🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma

Recruitingn/aAges 15 Years - 80 YearsAllSahlgrenska University Hospital
NCT07585032 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Insulinoma verified by pathology (often from EUS-FNB-sampling) Exclusion Criteria: * Patients unwilling to participate * Patients unable to understand and obtain written informed conscent * Severe comorbidity
💊

What it tests

  • EUS-RFA
📍

Where

1 site
Sahlgrenska Univeristy Hospital
Gothenburg, Sweden
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy